A Randomized Trial of Genotype-Guided Dosing of Warfarin by Pirmohamed Munir, Burnside Girvan, Eriksson Niclas, Jorgensen Andrea L, Toh Cheng Hock, Nicholson Toby, Kesteven Patrick, Christersson Christina, Wahlström Bengt, Stafberg Christina, Zhang J Eunice, Leathart Julian B, Kohnke Hugo, Maitland-van der Zee Anke H, Williamson Paula R, Daly Ann K, Avery Peter, Kamali Farhad, Wadelius Mia, the EU-PACT Group in The New England journal of medicine (2013).

[PMID: 24251363] PubMed

Abstract

Discussed In Paper

Loading...

Variant Annotations

Sign in to see variant annotations.

Rx Annotations

Rx Annotation for warfarin, CYP2C9 and VKORC1

Dosing algorithm

EU-PACT warfarin trial. For dosing algorithms see Table S1 (outside link to the New England Journal of Medicine)

Main findings

Mean percentage of time in the therapeutic range was 67.4% in the genotype-guided group compared to 60.3% in the control group (p<0.001) and the median time to reach a therapeutic international normalized ratio (INR) was 21 days in the genotype guided group compared to 29 days in the control group (p<0.001).

Additional findings

  • No. Study Subjects: genotype-guided group - 211, control group - 216
  • Ethnicity: Mixed (1.1% Black, 98.7% White, 0.4% Asian)
  • Indication: Atrial fibrillation or venous thromboembolism